NEW YORK, Feb. 10, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take place February 14-15 at the Waldorf-Astoria in New York. Dr. Robin Smith, MD, MBA, CEO of NeoStem, will present in the Duke of Windsor Room at 8 AM on Monday, February 14.
In recapping its recent highlights, the Company will review multiple accomplishments. In January 2011, the Company acquired Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized cell therapy services and development company that, through its cGMP certified manufacturing facilities and team of professionals, facilitates the preclinical and clinical development and eventual commercialization of cellular therapies for clients in the United States and internationally. In November 2010, the Company raised $19 million from two concurrent offerings. These funds supported the closing of the PCT acquisition and are helping the Company in growing its revenue lines of businesses in the US and China. Also in 2010, NeoStem was named "Best Stem Cell Company, 2010" in The New Economy's Biotech Awards. Additionally, the Vatican's Pontifical Council has undertaken to commit $1 million to joint ventures with NeoStem and the Stem for Life Foundation, a not-for-profit entity NeoStem participated in founding, to expand research and raise awareness of adult stem cell therapies.
In 2010, the Company also began generating revenues from what it believes will be the beginning of a pipeline of stem cell-based regenerative medicine therapies, a key element of its growth strategy in both the United States and China, with a collaboration with Wendeng Hospital in China whereby patients are being offered the benefit of the latest technology from the US in the treatment of a range of orthopedic conditions. Additionally, the ongoing relocation of Suzhou Erye Pharmaceutical's new manufacturing facility continues to progress and should be completed in 2011 thereby significantly increasing capacity.
Dr. Robin Smith said, "I look forward to telling the NeoStem story to BIO Conference attendees, including our diversified strategy in pharmaceuticals, cell therapy development, and adult stem cell collection and storage by our experienced team, which has deepened substantially with the acquisition of PCT."
About NeoStem, Inc.NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally. The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells, and a T-cell regulatory technology through the acquisition of Progenitor Cell Therapy, LLC.
For more information, please visit: http://www.neostem.com.
About the BIO CEO & Investor ConferenceThe BIO CEO & Investor Conference is a must attend event for institutional investors, industry analysts, and senior biotechnology executives focused on shaping the future investment landscape of the biotechnology industry. For more information on the conference, visit http://www.bio.org/bioceo. For the latest biotech data analysis and insights from BIO Industry Analysis, visit http://insidebioia.com/.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability of PCT's business to complement NeoStem's adult stem cell operations and successful execution of the Company's strategy, as well as other advances in the Company's business, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, its Form S-4/A filed with the Securities and Exchange Commission on December 3, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. NeoStem may experience difficulties in integrating PCT's business and could fail to realize potential benefits of the merger. Acquisitions may entail numerous risks for NeoStem, including difficulties in assimilating acquired operations, technologies or products, including the loss of key employees from acquired businesses.For more information, please contactNeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: firstname.lastname@example.orgWeb: http://www.neostem.com
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved